阿德福韦酯治疗HBV-YMDD变异疗效分析  

Analysis of the Efficacy of Adefovir Dipivoxil in Patients with Chronic Hepatitis B and HBV YMDD Mutation

作　　者：田珊红[1] 胡金华 刘亚丽[3] 

机构地区：[1]河北省唐山市传染病医院,河北唐山063000 [2]河北省唐山市开滦集团公司医院,河北唐山63000 [3]河北省唐山市华北煤炭医学院,河北唐山063000

出　　处：《湖南环境生物职业技术学院学报》2010年第1期33-35,共3页JOurnal of Hunan Environment Biological Polytechnic

摘　　要：目的:总结HBV YMDD变异的慢性乙型肝炎患者服用阿德福韦酯治疗效果.方法:选择未接受抗病毒治疗的YMDD变异患者及服用拉米夫定后发生YMDD变异患者共20例为研究对象,均服用阿德福韦酯12个月,治疗剂量为10 mg.d-1.分别于治疗开始及治疗后3、6个月及治疗结束检测ALT、AST、HBeAg及HBVDNA定量并进行比较分析.结果:HBV YMDD变异患者服用阿德福韦酯治疗后血清ALT、AST、及HBV DNA载量均明显下降(P均<0.05).到治疗终点,有55%(11/20)的患者ALT、AST恢复正常,45%的患者HBeAg转阴.结论:阿德福韦酯治疗HBV YMDD变异的慢性乙型肝炎患者效果肯定.表1,参4.Objective To analyze the efficacy of adefovir dipivoxil in patients with chronic hepatitis B and HBV YMDD mutation. Methods 20 patients with chronic hepatitis B and HBV YMDD mutation which happened before or after lamivudine treatment were selected, they were given adefovir dipivoxil （ dose was 10mg · d^- 1 ） for 12 months. ALT, AST, HBeAg and HBV DNA level were detected in their serum before and after drug treat- ment respectively. Results After adefovir dipivoxil treatment, the serum ALT, AST and HBV DNA level decreased in all patients（P 〈 0.05 for all. At the end of treatment, 55% （11/20） patients＇serum ALT and AST got normal. 45% （9/20） patients＇ HBeAg became negative. Conclusion The efficacy of adefovir dipivoxil in patients with chronic hepatitis B and HBV YMDD mutation is positive, ltab. , 4refs.

关 键 词：慢性乙型肝炎 YMDD变异 阿德福韦酯 HBEAG 

分 类 号：R51[医药卫生—内科学]